论文部分内容阅读
Patients with androgen withdrawal therapy develop androgen-independent prostate cancer associated with Bcl-2 up-regulation and resulting in disease progression and death.With the discovery of promising therapeutic agents,like BH3-only mimetic ABT-263 and proteasome inhibitor,alone or in combination with other chemotherapeutic agents have been developed and widely evaluated to against a broad spectrum cancer types including prostate cancer.